Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
allogeneic mononuclear cells (1 trial)
autologous cd34+ cells (1 trial)
bone marrow derived mesenchymal stem cells (1 trial)
cyclophosphamide (cytoxan) (1 trial)
gemcitabine (gemzar) (1 trial)
Adenocarcinoma (Phase 2)
Cardiomyopathies (Phase 2)
Cardiomyopathy, Dilated (Phase 2)
Trials (2 total)
Trial APIs (5 total)